Neuroimaging biomarkers of neurodegenerative diseases and dementia

Seminars in Neurology

Volumn 33, Issue 4, 2013, Pages 386-416

  Risacher, Shannon L ^a   Saykin, Andrew J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease (AD); amyotrophic lateral sclerosis (ALS); Cruetzfeldt Jakob disease (CJD); dementia; dementia with Lewy bodies (DLB); frontotemporal dementia (FTD); Gerstmann Straussler Scheinker disease (GSS); HIV associated neurocognitive disorder (HAND); Huntington's disease (HD); mild cognitive impairment (MCI); multiple sclerosis (MS); neuroimaging; Parkinson's disease (PD)

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; CHOLINE; GLUTAMIC ACID; GLUTAMINE; HUNTINGTIN; N ACETYLASPARTIC ACID; PRION PROTEIN; PROGRANULIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APHASIA; ARTICLE; BRAIN CORTEX ATROPHY; BRAIN METABOLISM; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA; GLUCOSE METABOLISM; HIV ASSOCIATED DEMENTIA; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; MILD COGNITIVE IMPAIRMENT; MOTOR NEURON DISEASE; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROGRESSIVE NONFLUENT APHASIA; SEMANTIC DEMENTIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULAR AMYLOIDOSIS; VISION;

AIDS DEMENTIA COMPLEX; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; BRAIN; DEMENTIA; DEMENTIA, VASCULAR; FRONTOTEMPORAL DEMENTIA; HUMANS; HUNTINGTON DISEASE; LEWY BODY DISEASE; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NEUROIMAGING; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PRION DISEASES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84887841767     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0033-1359312     Document Type: Article

References (427)

1. Letourneau-Guillon L., Wada R., Kucharczyk W. Imaging of prion diseases. J Magn Reson Imaging: 2012; 35 5 998 1012
2. Politis M., Piccini P. Positron emission tomography imaging in neurological disorders. J Neurol: 2012; 259 9 1769 1780
3. Alzheimer's Association Facts and Figures. Chicago, IL Alzheimer's Association: 2012
4. McKhann g. matter, Knopman D. S., Chertkow H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement: 2011; 7 3 263 269
5. Petersen R. C., Smith G. E., Waring S. C., Ivnik R. J., Tangalos E. G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol: 1999; 56 3 303 308 (Pubitemid 29120227)
6. Albert M. S., DeKosky S. T., Dickson D., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement: 2011; 7 3 270 279
7. Sperling R. A., Aisen P. S., Beckett L. A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement: 2011; 7 3 280 292
8. Jack C. R. Jr, Knopman D. S., Jagust W. J., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol: 2010; 9 1 119 128
9. Braak H., Braak E., Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol: 1993; 33 6 403 408 (Pubitemid 23358066)
10. Bateman R. J., Xiong C., Benzinger T. L., et al. Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med: 2012; 367 9 795 804
11. McGinnis S. M. Neuroimaging in neurodegenerative dementias. Semin Neurol: 2012; 32 4 347 360
12. Andrade K., Kas A., Valabrègue R., et al. Visuospatial deficits in posterior cortical atrophy: structural and functional correlates. J Neurol Neurosurg Psychiatry: 2012; 83 9 860 863
13. Rohrer J. D. Structural brain imaging in frontotemporal dementia. Biochim Biophys Acta: 2012; 1822 3 325 332
14. Viswanathan A., Greenberg S. M. Cerebral amyloid angiopathy in the elderly. Ann Neurol: 2011; 70 6 871 880
15. Kinnecom C., Lev M. H., Wendell L., et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology: 2007; 68 17 1411 1416 (Pubitemid 46661556)
16. Grossman M. Biomarkers to identify the pathological basis for frontotemporal lobar degeneration. J Mol Neurosci: 2011; 45 3 366 371
17. Whitwell J. L., Josephs K. A. Neuroimaging in frontotemporal lobar degeneration-predicting molecular pathology. Nat Rev Neurology: 2011; 8 3 131 142
18. Lomen-Hoerth C. Clinical phenomenology and neuroimaging correlates in ALS-FTD. J Mol Neurosci: 2011; 45 3 656 662
19. Trojsi F., Monsurrò M. R., Esposito F., Tedeschi G. Widespread structural and functional connectivity changes in amyotrophic lateral sclerosis: insights from advanced neuroimaging research. Neural Plast: 2012; 2012 473538
20. Watson R., Blamire A. M., O'Brien J. T. Magnetic resonance imaging in Lewy body dementias. Dement Geriatr Cogn Disord: 2009; 28 6 493 506
21. Silbert L. C., Kaye J. Neuroimaging and cognition in Parkinson's disease dementia. Brain Pathol: 2010; 20 3 646 653
22. Papp K. V., Kaplan R. F., Snyder P. J. Biological markers of cognition in prodromal Huntington's disease: a review. Brain Cogn: 2011; 77 2 280 291
23. Sá M. J. Physiopathology of symptoms and signs in multiple sclerosis. Arq Neuropsiquiatr: 2012; 70 9 733 740
24. Compston A., Coles A. Multiple sclerosis. Lancet: 2008; 372 9648 1502 1517
25. Nakahara J., Maeda M., Aiso S., Suzuki N. Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy. Clin Rev Allergy Immunol: 2012; 42 1 26 34
26. Lublin F. D., Reingold S. C.; National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology: 1996; 46 4 907 911 (Pubitemid 26134623)
27. Antinori A., Arendt G., Becker J. T., et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology: 2007; 69 18 1789 1799 (Pubitemid 350059308)
28. Tozzi V., Balestra P., Lorenzini P., et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol: 2005; 11 3 265 273 (Pubitemid 41122414)
29. Bonnet F., Amieva H., Marquant F., et al. S CO3 Aquitaine Cohort. Cognitive disorders in HIV-infected patients: are they HIV-related? AIDS: 2013; 27 3 391 400
30. Steinbrink F., Evers S., Buerke B., et al. German Competence Network HIV/AIDS Cognitive impairment in HIV infection is associated with MRI and CSF pattern of neurodegeneration. Eur J Neurol: 2013; 20 3 420 428
31. Robertson K., Liner J., Heaton R. Neuropsychological assessment of HIV-infected populations in international settings. Neuropsychol Rev: 2009; 19 2 232 249
32. Alsop D. C., Dai W., Grossman M., Detre J. A. Arterial spin labeling blood flow MRI: its role in the early characterization of Alzheimer's disease. J Alzheimers Dis: 2010; 20 3 871 880
33. Wang Y., Saykin A. J., Pfeuffer J., et al. Regional reproducibility of pulsed arterial spin labeling perfusion imaging at 3T. Neuroimage: 2011; 54 2 1188 1195
34. Ogawa S., Tank D. W., Menon R., et al. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci U S A: 1992; 89 13 5951 5955
35. Logothetis N. K., Pauls J., Augath M., Trinath T., Oeltermann A. Neurophysiological investigation of the basis of the fMRI signal. Nature: 2001; 412 6843 150 157 (Pubitemid 32674704)
36. Greicius M. D., Krasnow B., Reiss A. L., Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A: 2003; 100 1 253 258 (Pubitemid 36078061)
37. Jack C. R. Jr, Bernstein M. A., Borowski B. J., et al. Alzheimer's Disease Neuroimaging Initiative. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement: 2010; 6 3 212 220
38. Weiner M. W., Veitch D. P., Aisen P. S., et al. Alzheimer's Disease Neuroimaging Initiative The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement: 2013; Sept; 9 5 e111 e194
39. Risacher S. L., Saykin A. J., West J. D., Shen L., Firpi H. A., McDonald B. C.; Alzheimer's Disease Neuroimaging Initiative (ADNI). Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res: 2009; 6 4 347 361
40. Du A. T., Schuff N., Amend D., et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry: 2001; 71 4 441 447 (Pubitemid 32906865)
41. Chételat G., Desgranges B., De La Sayette V., Viader F., Eustache F., Baron J. C. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport: 2002; 13 15 1939 1943 (Pubitemid 35398965)
42. Hämäläinen A., Tervo S., Grau-Olivares M., et al. Voxel-based morphometry to detect brain atrophy in progressive mild cognitive impairment. Neuroimage: 2007; 37 4 1122 1131 (Pubitemid 47385281)
43. Whitwell J. L., Shiung M. M., Przybelski S. A., et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology: 2008; 70 7 512 520 (Pubitemid 351653375)
44. deToledo-Morrell L., Stoub T. R., Bulgakova M., et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging: 2004; 25 9 1197 1203 (Pubitemid 39094022)
45. Devanand D. P., Liu X., Tabert M. H., et al. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry: 2008; 64 10 871 879
46. Jack C. R. Jr, Petersen R. C., Xu Y. C., et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology: 1999; 52 7 1397 1403 (Pubitemid 29190530)
47. Barnes J., Bartlett J. W., van de Pol L. A., et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging: 2009; 30 11 1711 1723
48. Honea R. A., Vidoni E., Harsha A., Burns J. M. Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. J Alzheimers Dis: 2009; 18 3 553 564
49. Risacher S. L., Shen L., West J. D., et al. Alzheimer's Disease Neuroimaging Initiative (ADNI) Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging: 2010; 31 8 1401 1418
50. Donix M., Burggren A. C., Suthana N. A., et al. Longitudinal changes in medial temporal cortical thickness in normal subjects with the APOE-4 polymorphism. Neuroimage: 2010; 53 1 37 43
51. Wishart H. A., Saykin A. J., McAllister T. W., et al. Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele. Neurology: 2006; 67 7 1221 1224 (Pubitemid 44563831)
52. Chételat G., Villemagne V. L., Bourgeat P., et al. Australian Imaging Biomarkers and Lifestyle Research Group Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol: 2010; 67 3 317 324
53. Bourgeat P., Chételat G., Villemagne V. L., et al. AIBL Research Group Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology: 2010; 74 2 121 127
54. Jack C. R. Jr, Lowe V. J., Senjem M. L., et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain: 2008; 131 Pt 3 665 680 (Pubitemid 351294719)
55. Saykin A. J., Wishart H. A., Rabin L. A., et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology: 2006; 67 5 834 842 (Pubitemid 44394199)
56. Scheef L., Spottke A., Daerr M., et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology: 2012; 79 13 1332 1339
57. Striepens N., Scheef L., Wind A., et al. Volume loss of the medial temporal lobe structures in subjective memory impairment. Dement Geriatr Cogn Disord: 2010; 29 1 75 81
58. Ibrahim I., Horacek J., Bartos A., et al. Combination of voxel based morphometry and diffusion tensor imaging in patients with Alzheimer's disease. Neuroendocrinol Lett: 2009; 30 1 39 45
59. Rose S. E., McMahon K. L., Janke A. L., et al. Diffusion indices on magnetic resonance imaging and neuropsychological performance in amnestic mild cognitive impairment. J Neurol Neurosurg Psychiatry: 2006; 77 10 1122 1128 (Pubitemid 44453245)
60. Zhang Y., Schuff N., Jahng G. H., et al. Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology: 2007; 68 1 13 19 (Pubitemid 46058544)
61. Fellgiebel A., Wille P., Müller M. J., et al. Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study. Dement Geriatr Cogn Disord: 2004; 18 1 101 108 (Pubitemid 38822746)
62. Wang Y., West J. D., Flashman L. A., et al. Selective changes in white matter integrity in MCI and older adults with cognitive complaints. Biochim Biophys Acta: 2012; 1822 3 423 430
63. Chantal S., Braun C. M., Bouchard R. W., Labelle M., Boulanger Y. Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res: 2004; 1003 1-2 26 35 (Pubitemid 38317081)
64. Schuff N., Capizzano A. A., Du A. T., et al. Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology: 2002; 58 6 928 935 (Pubitemid 34242070)
65. Kantarci K., Jack C. R. Jr, Xu Y. C., et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology: 2000; 55 2 210 217 (Pubitemid 30604620)
66. Harris G. J., Lewis R. F., Satlin A., et al. Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine. AJNR Am J Neuroradiol: 1998; 19 9 1727 1732 (Pubitemid 30413765)
67. Celone K. A., Calhoun V. D., Dickerson B. C., et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci: 2006; 26 40 10222 10231 (Pubitemid 44527415)
68. Dickerson B. C., Salat D. H., Greve D. N., et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology: 2005; 65 3 404 411 (Pubitemid 41099803)
69. Johnson S. C., Schmitz T. W., Moritz C. H., et al. Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment. Neurobiol Aging: 2006; 27 11 1604 1612 (Pubitemid 44363104)
70. Trivedi M. A., Murphy C. M., Goetz C., et al. fMRI activation changes during successful episodic memory encoding and recognition in amnestic mild cognitive impairment relative to cognitively healthy older adults. Dement Geriatr Cogn Disord: 2008; 26 2 123 137
71. Saykin A. J., Flashman L. A., Frutiger S. A., et al. Neuroanatomic substrates of semantic memory impairment in Alzheimer's disease: patterns of functional MRI activation. J Int Neuropsychol Soc: 1999; 5 5 377 392 (Pubitemid 29385187)
72. Pariente J., Cole S., Henson R., et al. Alzheimer's patients engage an alternative network during a memory task. Ann Neurol: 2005; 58 6 870 879 (Pubitemid 41746876)
73. O'Brien J. L., O'Keefe K. M., LaViolette P. S., et al. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology: 2010; 74 24 1969 1976
74. Bookheimer S. Y., Strojwas M. H., Cohen M. S., et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med: 2000; 343 7 450 456 (Pubitemid 30646483)
75. Johnson S. C., Schmitz T. W., Trivedi M. A., et al. The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J Neurosci: 2006; 26 22 6069 6076 (Pubitemid 44334754)
76. Wishart H. A., Saykin A. J., Rabin L. A., et al. Increased brain activation during working memory in cognitively intact adults with the APOE epsilon4 allele. Am J Psychiatry: 2006; 163 9 1603 1610 (Pubitemid 44465762)
77. Johnson S. C., Saykin A. J., Baxter L. C., et al. The relationship between fMRI activation and cerebral atrophy: comparison of normal aging and Alzheimer disease. Neuroimage: 2000; 11 3 179 187 (Pubitemid 30164982)
78. Grady C. L., McIntosh A. R., Beig S., Keightley M. L., Burian H., Black S. E. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. J Neurosci: 2003; 23 3 986 993 (Pubitemid 36206190)
79. Zhou Y., Dougherty J. H. Jr, Hubner K. F., Bai B., Cannon R. L., Hutson R. K. Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer's disease and mild cognitive impairment. Alzheimers Dement: 2008; 4 4 265 270 (Pubitemid 351866121)
80. Buckner R. L., Snyder A. Z., Shannon B. J., et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci: 2005; 25 34 7709 7717 (Pubitemid 41208641)
81. Greicius M. D., Srivastava G., Reiss A. L., Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A: 2004; 101 13 4637 4642 (Pubitemid 38437463)
82. Bai F., Zhang Z., Watson D. R., et al. Abnormal functional connectivity of hippocampus during episodic memory retrieval processing network in amnestic mild cognitive impairment. Biol Psychiatry: 2009; 65 11 951 958
83. Sperling R. A., Laviolette P. S., O'Keefe K., et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron: 2009; 63 2 178 188
84. Rami L., Sala-Llonch R., Solé-Padullés C., et al. Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer's disease. J Alzheimers Dis: 2012; 31 3 517 526
85. Trachtenberg A. J., Filippini N., Ebmeier K. P., Smith S. M., Karpe F., Mackay C. E. The effects of APOE on the functional architecture of the resting brain. Neuroimage: 2012; 59 1 565 572
86. Wang Y., Risacher S. L., West J. D., et al. Altered default mode network connectivity in older adults with cognitive complaints and amnestic mild cognitive impairment. J Alzheimers Dis: 2013; 35 4 751 760
87. Langbaum J. B., Chen K., Lee W., et al. Alzheimer's Disease Neuroimaging Initiative Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage: 2009; 45 4 1107 1116
88. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging: 2005; 32 4 486 510 (Pubitemid 40591181)
89. Herholz K., Nordberg A., Salmon E., et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord: 1999; 10 6 494 504 (Pubitemid 29512018)
90. Alexander G. E., Chen K., Pietrini P., Rapoport S. I., Reiman E. M. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry: 2002; 159 5 738 745 (Pubitemid 34465046)
91. Small G. W., Ercoli L. M., Silverman D. H., et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A: 2000; 97 11 6037 6042 (Pubitemid 30367519)
92. de Leon M. J., Convit A., Wolf O. T., et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/ positron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A: 2001; 98 19 10966 10971 (Pubitemid 32878727)
93. Mosconi L., De Santi S., Brys M., et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry: 2008; 63 6 609 618 (Pubitemid 351273189)
94. Klunk W. E., Engler H., Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol: 2004; 55 3 306 319 (Pubitemid 38269583)
95. Jack C. R. Jr, Lowe V. J., Weigand S. D., et al. Alzheimer's Disease Neuroimaging Initiative Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain: 2009; 132 Pt 5 1355 1365
96. Johnson K. A., Fox N. C., Sperling R. A., Klunk W. E. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med: 2012; 2 4 a006213
97. Forsberg A., Engler H., Almkvist O., et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging: 2008; 29 10 1456 1465
98. Klunk W. E., Mathis C. A., Price J. C., Lopresti B. J., DeKosky S. T. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain: 2006; 129 Pt 11 2805 2807 (Pubitemid 44684503)
99. Reiman E. M., Chen K., Liu X., et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A: 2009; 106 16 6820 6825
100. Honea R. A., Vidoni E. D., Swerdlow R. H., Burns J. M.; Alzheimer's Disease Neuroimaging Initiative. Maternal family history is associated with Alzheimer's disease biomarkers. J Alzheimers Dis: 2012; 31 3 659 668
101. Mosconi L., Rinne J. O., Tsui W. H., et al. Increased fibrillar amyloid-beta burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A: 2010; 107 13 5949 5954
102. Rowe C. C., Ellis K. A., Rimajova M., et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging: 2010; 31 8 1275 1283
103. Clark C. M., Schneider J. A., Bedell B. J., et al. AV45-A07 Study Group. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA: 2011; 305 3 275 283
104. Rinne J. O., Kaasinen V., Järvenpää T., et al. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J Neurol Neurosurg Psychiatry: 2003; 74 1 113 115 (Pubitemid 36069048)
105. Herholz K., Weisenbach S., Kalbe E., Diederich N. J., Heiss W. D. Cerebral acetylcholine esterase activity in mild cognitive impairment. Neuroreport: 2005; 16 13 1431 1434 (Pubitemid 41805657)
106. Sabri O., Kendziorra K., Wolf H., Gertz H. J., Brust P. Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging: 2008; 35 01 S30 S45
107. Pappatà S., Salvatore E., Postiglione A. In vivo imaging of neurotransmission and brain receptors in dementia. J Neuroimaging: 2008; 18 2 111 124 (Pubitemid 351463968)
108. Hasselbalch S. G., Madsen K., Svarer C., et al. Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol Aging: 2008; 29 12 1830 1838
109. Edison P., Archer H. A., Gerhard A., et al. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis: 2008; 32 3 412 419
110. Okello A., Edison P., Archer H. A., et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology: 2009; 72 1 56 62
111. Wiley C. A., Lopresti B. J., Venneti S., et al. Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol: 2009; 66 1 60 67
112. Ringman J. M., O'Neill J., Geschwind D., et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain: 2007; 130 Pt 7 1767 1776 (Pubitemid 47343801)
113. Ringman J. M., Younkin S. G., Pratico D., et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology: 2008; 71 2 85 92
114. Fox N. C., Warrington E. K., Freeborough P. A., et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain: 1996; 119 Pt 6 2001 2007
115. Gregory G. C., Macdonald V., Schofield P. R., Kril J. J., Halliday g. matter. Differences in regional brain atrophy in genetic forms of Alzheimer's disease. Neurobiol Aging: 2006; 27 3 387 393 (Pubitemid 43186040)
116. Bateman R. J., Aisen P. S., De Strooper B., et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther: 2011; 3 1 1
117. Villemagne V. L., Ataka S., Mizuno T., et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol: 2009; 66 12 1537 1544
118. Migliaccio R., Agosta F., Scola E., et al. Ventral and dorsal visual streams in posterior cortical atrophy: a DT MRI study. Neurobiol Aging: 2012; 33 11 2572 2584
119. Lehmann M., Crutch S. J., Ridgway G. R., et al. Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer's disease. Neurobiol Aging: 2011; 32 8 1466 1476
120. de Souza L. C., Lehéricy S., Dubois B., Stella F., Sarazin M. Neuroimaging in dementias. Curr Opin Psychiatry: 2012; 25 6 473 479
121. Kas A., de Souza L. C., Samri D., et al. Neural correlates of cognitive impairment in posterior cortical atrophy. Brain: 2011; 134 Pt 5 1464 1478
122. Ng S. Y., Villemagne V. L., Masters C. L., Rowe C. C. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh compound B. Arch Neurol: 2007; 64 8 1140 1144 (Pubitemid 47258073)
123. Madhavan A., Whitwell J. L., Weigand S. D., et al. FDG PET and MRI in logopenic primary progressive aphasia versus dementia of the Alzheimer's type. PLoS ONE: 2013; 8 4 e62471
124. Mahoney C. J., Malone I. B., Ridgway G. R., et al. White matter tract signatures of the progressive aphasias. Neurobiol Aging: 2013; 34 6 1687 1699
125. Magnin E., Cattin F., Vandel P., Galmiche J., Moulin T., Rumbach L. Fractional anisotropy in three variants of primary progressive aphasia. Eur Neurol: 2012; 68 4 229 233
126. Rabinovici G. D., Jagust W. J., Furst A. J., et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol: 2008; 64 4 388 401
127. Wattjes M. P. Structural MRI. Int Psychogeriatr: 2011; Sept; 23 02 S13 S24
128. Tartaglia M. C., Rosen H. J., Miller B. L. Neuroimaging in dementia. Neurotherapeutics: 2011; 8 1 82 92
129. Dumas A., Dierksen G. A., Gurol M. E., et al. Functional magnetic resonance imaging detection of vascular reactivity in cerebral amyloid angiopathy. Ann Neurol: 2012; 72 1 76 81
130. Chung Y. A., O JH, Kim J. Y., et al. Hypoperfusion and ischemia in cerebral amyloid angiopathy documented by 99mTc-ECD brain perfusion SPECT. J Nucl Med: 2009; 50 12 1969 1974
131. Villemagne V. L., Rowe C. C. Amyloid imaging. Int Psychogeriatr: 2011; Sept; 23 02 S41 S49
132. Du A. T., Schuff N., Laakso M. P., et al. Effects of subcortical ischemic vascular dementia and AD on entorhinal cortex and hippocampus. Neurology: 2002; 58 11 1635 1641 (Pubitemid 34602894)
133. Eckerström C., Olsson E., Klasson N., et al. High white matter lesion load is associated with hippocampal atrophy in mild cognitive impairment. Dement Geriatr Cogn Disord: 2011; 31 2 132 138
134. Fein G., Di Sclafani V., Tanabe J., et al. Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology: 2000; 55 11 1626 1635
135. Jagust W. J., Zheng L., Harvey D. J., et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol: 2008; 63 1 72 80 (Pubitemid 351240553)
136. Mungas D., Jagust W. J., Reed B. R., et al. MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer's disease. Neurology: 2001; 57 12 2229 2235 (Pubitemid 34016456)
137. Scher A. I., Xu Y., Korf E. S., et al. Hippocampal morphometry in population-based incident Alzheimer's disease and vascular dementia: the HAAS. J Neurol Neurosurg Psychiatry: 2011; 82 4 373 376
138. Mori E. Impact of subcortical ischemic lesions on behavior and cognition. Ann N Y Acad Sci: 2002; 977 141 148 (Pubitemid 35418147)
139. van de Pol L. A., Korf E. S., van der Flier w. , et al. Magnetic resonance imaging predictors of cognition in mild cognitive impairment. Arch Neurol: 2007; 64 7 1023 1028 (Pubitemid 47048004)
140. Verdelho A., Madureira S., Moleiro C., et al. LADIS Study White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology: 2010; 75 2 160 167
141. Cho H., Kwon J. H., Seo H. J. Medial temporal lobe atrophy in vascular dementia: visual temporal lobe rating scale. Arch Gerontol Geriatr: 2009; 48 3 415 418
142. Li C., Du H., Zheng J., Wang J. A voxel-based morphometric analysis of cerebral gray matter in subcortical ischemic vascular dementia patients and normal aged controls. Int J Med Sci: 2011; 8 6 482 486
143. Seo S. W., Ahn J., Yoon U., et al. Cortical thinning in vascular mild cognitive impairment and vascular dementia of subcortical type. J Neuroimaging: 2010; 20 1 37 45
144. van de Pol L., Gertz H. J., Scheltens P., Wolf H. Hippocampal atrophy in subcortical vascular dementia. Neurodegener Dis: 2011; 8 6 465 469
145. Chen Y., Chen X., Xiao W., Mok V. C., Wong K. S., Tang W. K. Frontal lobe atrophy is associated with small vessel disease in ischemic stroke patients. Clin Neurol Neurosurg: 2009; 111 10 852 857
146. Looi J. C., Tatham V., Kumar R., et al. Caudate nucleus volumes in stroke and vascular dementia. Psychiatry Res: 2009; 174 1 67 75
147. Chen T. F., Lin C. C., Chen Y. F., et al. Diffusion tensor changes in patients with amnesic mild cognitive impairment and various dementias. Psychiatry Res: 2009; 173 1 15 21
148. Della Nave R., Foresti S., Pratesi A., et al. Whole-brain histogram and voxel-based analyses of diffusion tensor imaging in patients with leukoaraiosis: correlation with motor and cognitive impairment. AJNR Am J Neuroradiol: 2007; 28 7 1313 1319 (Pubitemid 47309665)
149. Fu J. L., Zhang T., Chang C., Zhang Y. Z., Li W. B. The value of diffusion tensor imaging in the differential diagnosis of subcortical ischemic vascular dementia and Alzheimer's disease in patients with only mild white matter alterations on T2-weighted images. Acta Radiol: 2012; 53 3 312 317
150. Kim S. H., Park J. S., Ahn H. J., et al. Voxel-based analysis of diffusion tensor imaging in patients with subcortical vascular cognitive impairment: correlates with cognitive and motor deficits. J Neuroimaging: 2011; 21 4 317 324
151. Nitkunan A., Barrick T. R., Charlton R. A., Clark C. A., Markus H. S. Multimodal MRI in cerebral small vessel disease: its relationship with cognition and sensitivity to change over time. Stroke: 2008; 39 7 1999 2005
152. O'Sullivan M., Morris R. G., Huckstep B., Jones D. K., Williams S. C., Markus H. S. Diffusion tensor MRI correlates with executive dysfunction in patients with ischaemic leukoaraiosis. J Neurol Neurosurg Psychiatry: 2004; 75 3 441 447 (Pubitemid 38338776)
153. O'Sullivan M., Summers P. E., Jones D. K., Jarosz J. M., Williams S. C., Markus H. S. Normal-appearing white matter in ischemic leukoaraiosis: a diffusion tensor MRI study. Neurology: 2001; 57 12 2307 2310 (Pubitemid 34016470)
154. Xu Q., Zhou Y., Li Y. S., et al. Diffusion tensor imaging changes correlate with cognition better than conventional MRI findings in patients with subcortical ischemic vascular disease. Dement Geriatr Cogn Disord: 2010; 30 4 317 326
155. Li C., Zheng J., Wang J., Gui L. Comparison between Alzheimer's disease and subcortical vascular dementia: attentional cortex study in functional magnetic resonance imaging. J Int Med Res: 2011; 39 4 1413 1419
156. Tak S., Yoon S. J., Jang J., Yoo K., Jeong Y., Ye J. C. Quantitative analysis of hemodynamic and metabolic changes in subcortical vascular dementia using simultaneous near-infrared spectroscopy and fMRI measurements. Neuroimage: 2011; 55 1 176 184
157. Sun Y. W., Qin L. D., Zhou Y., et al. Abnormal functional connectivity in patients with vascular cognitive impairment, no dementia: a resting-state functional magnetic resonance imaging study. Behav Brain Res: 2011; 223 2 388 394
158. Schuff N., Matsumoto S., Kmiecik J., et al. Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging. Alzheimers Dement: 2009; 5 6 454 462
159. Pakrasi S., O'Brien J. T. Emission tomography in dementia. Nucl Med Commun: 2005; 26 3 189 196 (Pubitemid 40411042)
160. Powers W. J., Zazulia A. R. PET in Cerebrovascular Disease. PET Clin: 2010; 5 1 83106
161. Heiss W. D., Zimmermann-Meinzingen S. PET imaging in the differential diagnosis of vascular dementia. J Neurol Sci: 2012; 322 1-2 268 273
162. Yoon C. W., Shin J. S., Kim H. J., et al. Cognitive deficits of pure subcortical vascular dementia vs. Alzheimer disease: PiB-PET-based study. Neurology: 2013; 80 6 569 573
163. Piguet O., Hornberger M., Mioshi E., Hodges J. R. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol: 2011; 10 2 162 172
164. Seelaar H., Rohrer J. D., Pijnenburg Y. A., Fox N. C., van Swieten J. C. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry: 2011; 82 5 476 486
165. Krueger C. E., Dean D. L., Rosen H. J., et al. Longitudinal rates of lobar atrophy in frontotemporal dementia, semantic dementia, and Alzheimer's disease. Alzheimer Dis Assoc Disord: 2010; 24 1 43 48
166. Whitwell J. L., Jack C. R. Jr, Parisi J. E., et al. Imaging signatures of molecular pathology in behavioral variant frontotemporal dementia. J Mol Neurosci: 2011; 45 3 372 378
167. Whitwell J. L., Josephs K. A., Rossor M. N., et al. Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. Arch Neurol: 2005; 62 9 1402 1408 (Pubitemid 41352057)
168. Ghetti B., Spina S., Murrell J. R., et al. In vivo and postmortem clinicoanatomical correlations in frontotemporal dementia and parkinsonism linked to chromosome 17. Neurodegener Dis: 2008; 5 3-4 215 217 (Pubitemid 351347854)
169. Whitwell J. L., Przybelski S. A., Weigand S. D., et al. Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain: 2009; 132 Pt 11 2932 2946
170. Whitwell J. L., Jack C. R. Jr, Parisi J. E., et al. Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration? Neurology: 2010; 75 24 2212 2220
171. Rohrer J. D., Geser F., Zhou J., et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology: 2010; 75 24 2204 2211
172. Rohrer J. D., Lashley T., Schott J. M., et al. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain: 2011; 134 Pt 9 2565 2581
173. Josephs K. A., Whitwell J. L., Parisi J. E., et al. Caudate atrophy on MRI is a characteristic feature of FTLD-FUS. Eur J Neurol: 2010; 17 7 969 975
174. Zhang Y., Schuff N., Ching C., et al. Joint assessment of structural, perfusion, and diffusion MRI in Alzheimer's disease and frontotemporal dementia. Int J Alzheimers Dis: 2011; 2011 546871
175. Whitwell J. L., Avula R., Senjem M. L., et al. Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia. Neurology: 2010; 74 16 1279 1287
176. Ebmeier K. P., Filippini N., Heise V., Sexton C. E. Other magnetic resonance imaging techniques. Int Psychogeriatr: 2011; 23 02 S50 S57
177. Dopper E. G., Rombouts S. A., Jiskoot L. C., et al. Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. Neurology: 2013; 80 9 814 823
178. Rombouts S. A., van Swieten J. C., Pijnenburg Y. A., Goekoop R., Barkhof F., Scheltens P. Loss of frontal fMRI activation in early frontotemporal dementia compared to early AD. Neurology: 2003; 60 12 1904 1908 (Pubitemid 36736004)
179. Virani K., Jesso S., Kertesz A., Mitchell D., Finger E. Functional neural correlates of emotional expression processing deficits in behavioural variant frontotemporal dementia. J Psychiatry Neurosci: 2013; 38 3 174 182
180. Seeley W. W., Menon V., Schatzberg A. F., et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci: 2007; 27 9 2349 2356 (Pubitemid 46340968)
181. Pievani M., de Haan W., Wu T., Seeley W. W., Frisoni G. B. Functional network disruption in the degenerative dementias. Lancet Neurol: 2011; 10 9 829 843
182. Filippi M., Agosta F., Scola E., et al. Functional network connectivity in the behavioral variant of frontotemporal dementia. Cortex: 2012
183. Seeley W. W., Crawford R., Rascovsky K., et al. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol: 2008; 65 2 249 255 (Pubitemid 351240789)
184. Zhou J., Greicius M. D., Gennatas E. D., et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain: 2010; 133 Pt 5 1352 1367
185. Whitwell J. L., Josephs K. A., Avula R., et al. Altered functional connectivity in asymptomatic MAPT subjects: a comparison to bvFTD. Neurology: 2011; 77 9 866 874
186. Du A. T., Jahng G. H., Hayasaka S., et al. Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI. Neurology: 2006; 67 7 1215 1220 (Pubitemid 44563830)
187. Mummery C. J., Patterson K., Price C. J., Ashburner J., Frackowiak R. S., Hodges J. R. A voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory. Ann Neurol: 2000; 47 1 36 45 (Pubitemid 30033648)
188. Bonner M. F., Vesely L., Price C., et al. Reversal of the concreteness effect in semantic dementia. Cogn Neuropsychol: 2009; 26 6 568 579
189. Hodges J. R., Patterson K. Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol: 2007; 6 11 1004 1014 (Pubitemid 47562322)
190. Rohrer J. D., Warren J. D., Modat M., et al. Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration. Neurology: 2009; 72 18 1562 1569
191. Czarnecki K., Duffy J. R., Nehl C. R., et al. Very early semantic dementia with progressive temporal lobe atrophy: an 8-year longitudinal study. Arch Neurol: 2008; 65 12 1659 1663
192. Maguire E. A., Kumaran D., Hassabis D., Kopelman M. D. Autobiographical memory in semantic dementia: a longitudinal fMRI study. Neuropsychologia: 2010; 48 1 123 136
193. Goll J. C., Ridgway G. R., Crutch S. J., Theunissen F. E., Warren J. D. Nonverbal sound processing in semantic dementia: a functional MRI study. Neuroimage: 2012; 61 1 170 180
194. Wilson S. M., Brambati S. M., Henry R. G., et al. The neural basis of surface dyslexia in semantic dementia. Brain: 2009; 132 Pt 1 71 86
195. Farb N. A., Grady C. L., Strother S., et al. Abnormal network connectivity in frontotemporal dementia: evidence for prefrontal isolation. Cortex: 2013; 49 7 1856 1873
196. Josephs K. A., Duffy J. R., Strand E. A., et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain: 2006; 129 Pt 6 1385 1398 (Pubitemid 43999372)
197. Peelle J. E., Troiani V., Gee J., et al. Sentence comprehension and voxel-based morphometry in progressive nonfluent aphasia, semantic dementia, and nonaphasic frontotemporal dementia. J Neurolinguist: 2008; 21 5 418 432
198. Cooke A., DeVita C., Gee J., et al. Neural basis for sentence comprehension deficits in frontotemporal dementia. Brain Lang: 2003; 85 2 211 221 (Pubitemid 36542856)
199. Caso F., Gesierich B., Henry M., et al. Nonfluent/agrammatic PPA with in-vivo cortical amyloidosis and Pick's disease pathology. Behav Neurol: 2013; 26 1-2 95 106
200. Nestor P. J., Graham N. L., Fryer T. D., Williams G. B., Patterson K., Hodges J. R. Progressive non-fluent aphasia is associated with hypometabolism centred on the left anterior insula. Brain: 2003; 126 Pt 11 2406 2418 (Pubitemid 37314431)
201. Gil-Navarro S., Lomeña F., Cot A., et al. Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia. Eur J Neurol: 2013
202. Josephs K. A., Whitwell J. L., Dickson D. W., et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging: 2008; 29 2 280 289
203. Whitwell J. L., Jack C. R. Jr, Parisi J. E., et al. Rates of cerebral atrophy differ in different degenerative pathologies. Brain: 2007; 130 Pt 4 1148 1158 (Pubitemid 47355599)
204. Tokumaru A. M., Saito Y., Murayama S., et al. Imaging-pathologic correlation in corticobasal degeneration. AJNR Am J Neuroradiol: 2009; 30 10 1884 1892
205. Erbetta A., Mandelli M. L., Savoiardo M., et al. Diffusion tensor imaging shows different topographic involvement of the thalamus in progressive supranuclear palsy and corticobasal degeneration. AJNR Am J Neuroradiol: 2009; 30 8 1482 1487
206. Dashjamts T., Yoshiura T., Hiwatashi A., et al. Asymmetrical cerebral perfusion demonstrated by noninvasive arterial spin-labeling perfusion imaging in a patient with corticobasal degeneration. Jpn J Radiol: 2010; 28 1 75 78
207. Cilia R., Rossi C., Frosini D., et al. Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. PLoS ONE: 2011; 6 5 e18301
208. Mazère J., Meissner W. G., Mayo W., et al. Progressive supranuclear palsy: in vivo SPECT imaging of presynaptic vesicular acetylcholine transporter with [123I]-iodobenzovesamicol. Radiology: 2012; 265 2 537 543
209. Teune L. K., Bartels A. L., de Jong B. M., et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord: 2010; 25 14 2395 2404
210. Kuwahara H., Tsuchiya K., Saito Y., et al. Frontotemporal lobar degeneration with motor neuron disease showing severe and circumscribed atrophy of anterior temporal lobes. J Neurol Sci: 2010; 297 1-2 92 96
211. Turner M. R., Agosta F., Bede P., Govind V., Lulé D., Verstraete E. Neuroimaging in amyotrophic lateral sclerosis. Biomarkers Med: 2012; 6 3 319 337
212. Sage C. A., Peeters R. R., Görner A., Robberecht W., Sunaert S. Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis. Neuroimage: 2007; 34 2 486 499 (Pubitemid 44830171)
213. Sage C. A., Van Hecke W., Peeters R., et al. Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis: revisited. Hum Brain Mapp: 2009; 30 11 3657 3675
214. Sarro L., Agosta F., Canu E., et al. Cognitive functions and white matter tract damage in amyotrophic lateral sclerosis: a diffusion tensor tractography study. AJNR Am J Neuroradiol: 2011; 32 10 1866 1872
215. Abrahams S., Goldstein L. H., Kew J. J., et al. Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Brain: 1996; 119 Pt 6 2105 2120
216. Abrahams S., Leigh P. N., Kew J. J., Goldstein L. H., Lloyd C. M., Brooks D. J. A positron emission tomography study of frontal lobe function (verbal fluency) in amyotrophic lateral sclerosis. J Neurol Sci: 1995; 129 (Suppl): 44 46
217. Abrahams S., Goldstein L. H., Simmons A., et al. Word retrieval in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Brain: 2004; 127 Pt 7 1507 1517 (Pubitemid 38899404)
218. Palmieri A., Naccarato M., Abrahams S., et al. Right hemisphere dysfunction and emotional processing in ALS: an fMRI study. J Neurol: 2010; 257 12 1970 1978
219. Mohammadi B., Kollewe K., Samii A., Krampfl K., Dengler R., Münte T. F. Changes of resting state brain networks in amyotrophic lateral sclerosis. Exp Neurol: 2009; 217 1 147 153
220. Guedj E., Le Ber I., Lacomblez L., et al. French Research Network on FTD/FTD-MND Brain spect perfusion of frontotemporal dementia associated with motor neuron disease. Neurology: 2007; 69 5 488 490 (Pubitemid 47450285)
221. Talbot P. R., Goulding P. J., Lloyd J. J., Snowden J. S., Neary D., Testa H. J. Inter-relation between classic motor neuron disease and frontotemporal dementia: neuropsychological and single photon emission computed tomography study. J Neurol Neurosurg Psychiatry: 1995; 58 5 541 547
222. Ishikawa T., Morita M., Nakano I. Constant blood flow reduction in premotor frontal lobe regions in ALS with dementia - a SPECT study with 3D-SSP. Acta Neurol Scand: 2007; 116 5 340 344 (Pubitemid 47537411)
223. Garraux G., Salmon E., Degueldre C., Lemaire C., Franck G. Medial temporal lobe metabolic impairment in dementia associated with motor neuron disease. J Neurol Sci: 1999; 168 2 145 150 (Pubitemid 29467434)
224. Jeong Y., Park K. C., Cho S. S., et al. Pattern of glucose hypometabolism in frontotemporal dementia with motor neuron disease. Neurology: 2005; 64 4 734 736 (Pubitemid 40261911)
225. Ludolph A. C., Langen K. J., Regard M., et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand: 1992; 85 2 81 89
226. Lloyd C. M., Richardson M. P., Brooks D. J., Al-Chalabi A., Leigh P. N. Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain: 2000; 123 Pt 11 2289 2296
227. Sha S. J., Takada L. T., Rankin K. P., et al. Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. Neurology: 2012; 79 10 1002 1011
228. Yokoyama J. S., Rosen H. J. Neuroimaging features of C9ORF72 expansion. Alzheimers Res Ther: 2012; 4 6 45
229. Kassubek J., Unrath A., Huppertz H. J., et al. Global brain atrophy and corticospinal tract alterations in ALS, as investigated by voxel-based morphometry of 3-D MRI. Amyotroph Lateral Scler Other Motor Neuron Disord: 2005; 6 4 213 220
230. Chen Z., Ma L. Grey matter volume changes over the whole brain in amyotrophic lateral sclerosis: A voxel-wise meta-analysis of voxel based morphometry studies. Amyotroph Lateral Scler: 2010; 11 6 549 554
231. Roccatagliata L., Bonzano L., Mancardi G., Canepa C., Caponnetto C. Detection of motor cortex thinning and corticospinal tract involvement by quantitative MRI in amyotrophic lateral sclerosis. Amyotroph Lateral Scler: 2009; 10 1 47 52
232. Filippini N., Douaud G., Mackay C. E., Knight S., Talbot K., Turner M. R. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology: 2010; 75 18 1645 1652
233. Menke R. A., Abraham I., Thiel C. S., et al. Fractional anisotropy in the posterior limb of the internal capsule and prognosis in amyotrophic lateral sclerosis. Arch Neurol: 2012; 69 11 1493 1499
234. Li J., Pan P., Song W., Huang R., Chen K., Shang H. A meta-analysis of diffusion tensor imaging studies in amyotrophic lateral sclerosis. Neurobiol Aging: 2012; 33 8 1833 1838
235. Konrad C., Henningsen H., Bremer J., et al. Pattern of cortical reorganization in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Exp Brain Res: 2002; 143 1 51 56 (Pubitemid 34516358)
236. Han J., Ma L. Functional magnetic resonance imaging study of the brain in patients with amyotrophic lateral sclerosis. Chin Med Sci J: 2006; 21 4 228 233 (Pubitemid 46133454)
237. Stanton B. R., Williams V. C., Leigh P. N., et al. Altered cortical activation during a motor task in ALS. Evidence for involvement of central pathways. J Neurol: 2007; 254 9 1260 1267 (Pubitemid 350112355)
238. Konrad C., Jansen A., Henningsen H., et al. Subcortical reorganization in amyotrophic lateral sclerosis. Exp Brain Res: 2006; 172 3 361 369 (Pubitemid 43876052)
239. Lulé D., Diekmann V., Müller H. P., Kassubek J., Ludolph A. C., Birbaumer N. Neuroimaging of multimodal sensory stimulation in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry: 2010; 81 8 899 906
240. Jelsone-Swain L. M., Fling B. W., Seidler R. D., Hovatter R., Gruis K., Welsh R. C. Reduced Interhemispheric Functional Connectivity in the Motor Cortex during Rest in Limb-Onset Amyotrophic Lateral Sclerosis. Front Syst Neurosci: 2010; 4 158
241. Agosta F., Valsasina P., Absinta M., et al. Sensorimotor functional connectivity changes in amyotrophic lateral sclerosis. Cereb Cortex: 2011; 21 10 2291 2298
242. Han J., Ma L. Study of the features of proton MR spectroscopy ((1)H-MRS) on amyotrophic lateral sclerosis. J Magn Reson Imaging: 2010; 31 2 305 308
243. Schuff N., Rooney W. D., Miller R., et al. Reanalysis of multislice (1)H MRSI in amyotrophic lateral sclerosis. Magn Reson Med: 2001; 45 3 513 516 (Pubitemid 32173280)
244. Yin H., Lim C. C., Ma L., et al. Combined MR spectroscopic imaging and diffusion tensor MRI visualizes corticospinal tract degeneration in amyotrophic lateral sclerosis. J Neurol: 2004; 251 10 1249 1254 (Pubitemid 39517929)
245. Lombardo F., Frijia F., Bongioanni P., et al. Diffusion tensor MRI and MR spectroscopy in long lasting upper motor neuron involvement in amyotrophic lateral sclerosis. Arch Ital Biol: 2009; 147 3 69 82
246. Ludolph A. C., Elger C. E., Böttger I. W., Kuttig A. G., Lottes G., Brune G. G. N-isopropyl-p-123I-amphetamine single photon emission computer tomography in motor neuron disease. Eur Neurol: 1989; 29 5 255 260 (Pubitemid 19225868)
247. Tanaka M., Kondo S., Hirai S., Sun X., Yamagishi T., Okamoto K. Cerebral blood flow and oxygen metabolism in progressive dementia associated with amyotrophic lateral sclerosis. J Neurol Sci: 1993; 120 1 22 28 (Pubitemid 24011143)
248. Kew J. J., Goldstein L. H., Leigh P. N., et al. The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. Brain: 1993; 116 Pt 6 1399 1423 (Pubitemid 24038859)
249. Takahashi H., Snow B. J., Bhatt M. H., Peppard R., Eisen A., Calne D. B. Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning. Lancet: 1993; 342 8878 1016 1018 (Pubitemid 23314803)
250. Turner M. R., Gerhard A., Al-Chalabi A., et al. Mills' and other isolated upper motor neurone syndromes: in vivo study with 11C-(R)-PK11195 PET. J Neurol Neurosurg Psychiatry: 2005; 76 6 871 874 (Pubitemid 40805823)
251. Turner M. R., Cagnin A., Turkheimer F. E., et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis: 2004; 15 3 601 609 (Pubitemid 38429975)
252. Monchi O., Degroot C., Mejia-Constain B., Bruneau M. A. Neuroimaging studies of different cognitive profiles in Parkinson's disease. Parkinsonism Relat Disord: 2012; 18 01 S77 S79
253. Tateno M., Kobayashi S., Saito T. Imaging improves diagnosis of dementia with lewy bodies. Psychiatry Investig: 2009; 6 4 233 240
254. Hashimoto M., Kitagaki H., Imamura T., et al. Medial temporal and whole-brain atrophy in dementia with Lewy bodies: a volumetric MRI study. Neurology: 1998; 51 2 357 362 (Pubitemid 28406306)
255. Burton E. J., Karas G., Paling S. M., et al. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage: 2002; 17 2 618 630 (Pubitemid 35316999)
256. Ballmaier M., O'Brien J. T., Burton E. J., et al. Comparing gray matter loss profiles between dementia with Lewy bodies and Alzheimer's disease using cortical pattern matching: diagnosis and gender effects. Neuroimage: 2004; 23 1 325 335 (Pubitemid 39119463)
257. Burton E. J., McKeith I. G., Burn D. J., Williams E. D., O'Brien J. T. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain: 2004; 127 Pt 4 791 800 (Pubitemid 38478524)
258. Johansen K. K., White L. R., Sando S. B., Aasly J. O. Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. Parkinsonism Relat Disord: 2010; 16 5 307 315
259. Beyer M. K., Larsen J. P., Aarsland D. Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology: 2007; 69 8 747 754 (Pubitemid 47300931)
260. Shimada H., Shinotoh H., Hirano S., et al. β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. Mov Disord: 2013; 28 2 169 175
261. Burton E. J., McKeith I. G., Burn D. J., O'Brien J. T. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord: 2005; 20 12 1571 1576
262. O'Brien J. T., Paling S., Barber R., et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology: 2001; 56 10 1386 1388 (Pubitemid 32455303)
263. Lee J. E., Park H. J., Park B., et al. A comparative analysis of cognitive profiles and white-matter alterations using voxel-based diffusion tensor imaging between patients with Parkinson's disease dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry: 2010; 81 3 320 326
264. Bozzali M., Cherubini A. Diffusion tensor MRI to investigate dementias: a brief review. Magn Reson Imaging: 2007; 25 6 969 977 (Pubitemid 47081370)
265. Bozzali M., Falini A., Cercignani M., et al. Brain tissue damage in dementia with Lewy bodies: an in vivo diffusion tensor MRI study. Brain: 2005; 128 Pt 7 1595 1604 (Pubitemid 41373678)
266. Firbank M. J., Blamire A. M., Krishnan M. S., et al. Atrophy is associated with posterior cingulate white matter disruption in dementia with Lewy bodies and Alzheimer's disease. Neuroimage: 2007; 36 1 1 7 (Pubitemid 46617956)
267. Matsui H., Nishinaka K., Oda M., Niikawa H., Kubori T., Udaka F. Dementia in Parkinson's disease: diffusion tensor imaging. Acta Neurol Scand: 2007; 116 3 177 181 (Pubitemid 47262765)
268. Griffith H. R., den Hollander J. A., Okonkwo O. C., O'Brien T., Watts R. L., Marson D. C. Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia. Alzheimers Dement: 2008; 4 6 421 427
269. Griffith H. R., den Hollander J. A., Okonkwo O. C., O'Brien T., Watts R. L., Marson D. C. Brain N-acetylaspartate is reduced in Parkinson disease with dementia. Alzheimer Dis Assoc Disord: 2008; 22 1 54 60 (Pubitemid 351651398)
270. Griffith H. R., Okonkwo O. C., O'Brien T., Hollander J. A. Reduced brain glutamate in patients with Parkinson's disease. NMR Biomed: 2008; 21 4 381 387 (Pubitemid 351771888)
271. Sauer J., ffytche D. H., Ballard C., Brown R. G., Howard R. Differences between Alzheimer's disease and dementia with Lewy bodies: an fMRI study of task-related brain activity. Brain: 2006; 129 Pt 7 1780 1788 (Pubitemid 43999411)
272. Taylor J. P., Firbank M. J., He J., et al. Visual cortex in dementia with Lewy bodies: magnetic resonance imaging study. Br J Psychiatry: 2012; 200 6 491 498
273. Monchi O., Petrides M., Doyon J., Postuma R. B., Worsley K., Dagher A. Neural bases of set-shifting deficits in Parkinson's disease. J Neurosci: 2004; 24 3 702 710 (Pubitemid 38166496)
274. Galvin J. E., Price J. L., Yan Z., Morris J. C., Sheline Y. I. Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease. Neurology: 2011; 76 21 1797 1803
275. Torosyan N., Silverman D. H. Neuronuclear imaging in the evaluation of dementia and mild decline in cognition. Semin Nucl Med: 2012; 42 6 415 422
276. Kantarci K., Lowe V. J., Boeve B. F., et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging: 2012; 33 9 2091 2105
277. Gilman S., Koeppe R. A., Little R., et al. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol: 2005; 191 01 S95 S103 (Pubitemid 40081108)
278. Peppard R. F., Martin W. R., Carr G. D., et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol: 1992; 49 12 1262 1268
279. Schapiro M. B., Pietrini P., Grady C. L., et al. Reductions in parietal and temporal cerebral metabolic rates for glucose are not specific for Alzheimer's disease. J Neurol Neurosurg Psychiatry: 1993; 56 8 859 864 (Pubitemid 23246143)
280. Vander Borght T., Minoshima S., Giordani B., et al. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med: 1997; 38 5 797 802
281. O'Brien J. T., Colloby S., Fenwick J., et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol: 2004; 61 6 919 925 (Pubitemid 38747333)
282. Rinne J. O., Portin R., Ruottinen H., et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol: 2000; 57 4 470 475 (Pubitemid 30212118)
283. Brooks D. J., Pavese N. Imaging biomarkers in Parkinson's disease. Prog Neurobiol: 2011; 95 4 614 628
284. Mori T., Maeda J., Shimada H., et al. Molecular imaging of dementia. Psychogeriatrics: 2012; 12 2 106 114
285. Bohnen N. I., Kaufer D. I., Hendrickson R., et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol: 2006; 253 2 242 247 (Pubitemid 43255898)
286. Bohnen N. I., Kaufer D. I., Ivanco L. S., et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol: 2003; 60 12 1745 1748 (Pubitemid 37521630)
287. Hilker R., Thomas A. V., Klein J. C., et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology: 2005; 65 11 1716 1722
288. Bouchard T. P., Malykhin N., Martin W. R., et al. Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. Neurobiol Aging: 2008; 29 7 1027 1039 (Pubitemid 351697990)
289. Brück A., Kurki T., Kaasinen V., Vahlberg T., Rinne J. O. Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry: 2004; 75 10 1467 1469 (Pubitemid 39279819)
290. Camicioli R., Moore M. M., Kinney A., Corbridge E., Glassberg K., Kaye J. A. Parkinson's disease is associated with hippocampal atrophy. Mov Disord: 2003; 18 7 784 790 (Pubitemid 36939973)
291. Hu M. T., White S. J., Chaudhuri K. R., Morris R. G., Bydder g. matter, Brooks D. J. Correlating rates of cerebral atrophy in Parkinson's disease with measures of cognitive decline. J Neural Transm: 2001; 108 5 571 580 (Pubitemid 32441872)
292. Hu M. T., Taylor-Robinson S. D., Chaudhuri K. R., et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain: 2000; 123 Pt 2 340 352 (Pubitemid 30055157)
293. Huang C., Tang C., Feigin A., et al. Changes in network activity with the progression of Parkinson's disease. Brain: 2007; 130 Pt 7 1834 1846 (Pubitemid 47343798)
294. Fearnley J. M., Lees A. J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain: 1991; 114 Pt 5 2283 2301
295. Morrish P. K., Rakshi J. S., Bailey D. L., Sawle G. V., Brooks D. J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry: 1998; 64 3 314 319
296. Rinne J. O., Laihinen A., Rinne U. K., Någren K., Bergman J., Ruotsalainen U. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Mov Disord: 1993; 8 2 134 138 (Pubitemid 23131632)
297. Sawle G. V. The detection of preclinical Parkinson's disease: what is the role of positron emission tomography? Mov Disord: 1993; 8 3 271 277 (Pubitemid 23212534)
298. Kaasinen V., Någren K., Hietala J., et al. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology: 2000; 54 7 1482 1487 (Pubitemid 30210470)
299. Kaasinen V., Aalto S., NAgren K., Hietala J., Sonninen P., Rinne J. O. Extrastriatal dopamine D(2) receptors in Parkinson's disease: a longitudinal study. J Neural Transm: 2003; 110 6 591 601 (Pubitemid 36683513)
300. Guttman M., Boileau I., Warsh J., et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol: 2007; 14 5 523 528 (Pubitemid 46587839)
301. Asahina M., Suhara T., Shinotoh H., Inoue O., Suzuki K., Hattori T. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry: 1998; 65 2 155 163 (Pubitemid 28371923)
302. Shtilbans A., Henchcliffe C. Biomarkers in Parkinson's disease: an update. Curr Opin Neurol: 2012; 25 4 460 465
303. Piccini P., Weeks R. A., Brooks D. J. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol: 1997; 42 5 720 726 (Pubitemid 27481544)
304. Gerhard A., Pavese N., Hotton G., et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis: 2006; 21 2 404 412 (Pubitemid 43099863)
305. Ouchi Y., Yoshikawa E., Sekine Y., et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol: 2005; 57 2 168 175 (Pubitemid 40179853)
306. Georgiou-Karistianis N., Scahill R., Tabrizi S. J., Squitieri F., Aylward E. Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials. Neurosci Biobehav Rev: 2013; 37 3 480 490
307. Paulsen J. S., Langbehn D. R., Stout J. C., et al. Predict-HD Investigators and Coordinators of the Huntington Study Group Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry: 2008; 79 8 874 880
308. Paulsen J. S., Nopoulos P. C., Aylward E., et al. PREDICT-HD Investigators and Coordinators of the Huntington's Study Group (HSG) Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull: 2010; 82 3-4 201 207
309. Tabrizi S. J., Langbehn D. R., Leavitt B. R., et al. TRACK-HD investigators Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol: 2009; 8 9 791 801
310. Tabrizi S. J., Reilmann R., Roos R. A., et al. TRACK-HD investigators Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24. month observational data. Lancet Neurol: 2012; 11 1 42 53
311. Majid D. S., Aron A. R., Thompson W., et al. Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation. Mov Disord: 2011; 26 14 2544 2551
312. Tabrizi S. J., Scahill R. I., Durr A., et al. TRACK-HD Investigators Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol: 2011; 10 1 31 42
313. Henley S. M., Wild E. J., Hobbs N. Z., et al. Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord: 2009; 24 6 932 936
314. Hobbs N. Z., Pedrick A. V., Say M. J., et al. The structural involvement of the cingulate cortex in premanifest and early Huntington's disease. Mov Disord: 2011; 26 9 1684 1690
315. Rupp J., Dzemidzic M., Blekher T., et al. Comparison of vertical and horizontal saccade measures and their relation to gray matter changes in
316. Magnotta V. A., Kim J., Koscik T., et al. Diffusion Tensor Imaging in Preclinical Huntington's Disease. Brain Imaging Behav: 2009; 3 1 77 84
317. Reading S. A., Yassa M. A., Bakker A., et al. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res: 2005; 140 1 55 62 (Pubitemid 41443496)
318. Rosas H. D., Tuch D. S., Hevelone N. D., et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord: 2006; Sept; 21 9 1317 1325 (Pubitemid 44613279)
319. Klöppel S., Henley S. M., Hobbs N. Z., et al. Magnetic resonance imaging of Huntington's disease: preparing for clinical trials. Neuroscience: 2009; 164 1 205 219
320. Rupp J., Dzemidzic M., Blekher T., et al. Abnormal error-related antisaccade activation in premanifest and early manifest Huntington disease. Neuropsychology: 2011; 25 3 306 318
321. Unschuld P. G., Joel S. E., Liu X., et al. Impaired cortico-striatal functional connectivity in prodromal Huntington's Disease. Neurosci Lett: 2012; 514 2 204 209
322. Wolf R. C., Sambataro F., Vasic N., et al. Default-mode network changes in preclinical Huntington's disease. Exp Neurol: 2012; 237 1 191 198
323. Weeks R. A., Ceballos-Baumann A., Piccini P., Boecker H., Harding A. E., Brooks D. J. Cortical control of movement in Huntington's disease. A PET activation study. Brain: 1997; Nov; 120 Pt 9 1569 1578 (Pubitemid 27389224)
324. Feigin A., Leenders K. L., Moeller J. R., et al. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J Nucl Med: 2001; Nov; 42 11 1591 1595 (Pubitemid 33131316)
325. Ginovart N., Lundin A., Farde L., et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain: 1997; 120 Pt 3 503 514 (Pubitemid 27153642)
326. Antonini A., Leenders K. L., Eidelberg D. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol: 1998; 43 2 253 255 (Pubitemid 28110128)
327. Andrews T. C., Weeks R. A., Turjanski N., et al. Huntington's disease progression. PET and clinical observations. Brain: 1999; 122 Pt 12 2353 2363
328. Pavese N., Andrews T. C., Brooks D. J., et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain: 2003; 126 Pt 5 1127 1135 (Pubitemid 36522955)
329. Pavese N., Politis M., Tai Y. F., et al. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol Dis: 2010; 37 2 356 361
330. Tai Y. F., Pavese N., Gerhard A., et al. Imaging microglial activation in Huntington's disease. Brain Res Bull: 2007; 72 2-3 148 151 (Pubitemid 46389550)
331. Tai Y. F., Pavese N., Gerhard A., et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain: 2007; 130 Pt 7 1759 1766 (Pubitemid 47343790)
332. Politis M., Pavese N., Tai Y. F., et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp: 2011; 32 2 258 270
333. Pavese N., Gerhard A., Tai Y. F., et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology: 2006; 66 11 1638 1643 (Pubitemid 43964614)
334. Sbardella E., Petsas N., Tona F., et al. Assessing the correlation between grey and white matter damage with motor and cognitive impairment in multiple sclerosis patients. PLoS ONE: 2013; 8 5 e63250
335. Ceccarelli A., Bakshi R., Neema M. MRI in multiple sclerosis: a review of the current literature. Curr Opin Neurol: 2012; 25 4 402 409
336. Filippi M., Rocca M. A., De Stefano N., et al. Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol: 2011; 68 12 1514 1520
337. Rocca M. A., Mesaros S., Pagani E., Sormani M. P., Comi G., Filippi M. Thalamic damage and long-term progression of disability in multiple sclerosis. Radiology: 2010; 257 2 463 469
338. Sbardella E., Tona F., Petsas N., Pantano P. DTI Measurements in Multiple Sclerosis: Evaluation of Brain Damage and Clinical Implications. Mult Scler Int: 2013; 2013 671730, Epub 2013 Mar 31
339. Filippi M., Tortorella C., Rovaris M., et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry: 2000; 68 2 157 161 (Pubitemid 30245837)
340. Cercignani M., Inglese M., Pagani E., Comi G., Filippi M. Mean diffusivity and fractional anisotropy histograms of patients with multiple sclerosis. AJNR Am J Neuroradiol: 2001; 22 5 952 958 (Pubitemid 32436241)
341. Bozzali M., Cercignani M., Sormani M. P., Comi G., Filippi M. Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol: 2002; 23 6 985 988 (Pubitemid 34663445)
342. Vrenken H., Pouwels P. J., Geurts J. J., et al. Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration. J Magn Reson Imaging: 2006; 23 5 628 636
343. Ceccarelli A., Rocca M. A., Valsasina P., et al. A multiparametric evaluation of regional brain damage in patients with primary progressive multiple sclerosis. Hum Brain Mapp: 2009; 30 9 3009 3019
344. Preziosa P., Rocca M. A., Mesaros S., et al. Intrinsic damage to the major white matter tracts in patients with different clinical phenotypes of multiple sclerosis: a voxelwise diffusion-tensor MR study. Radiology: 2011; 260 2 541 550
345. Kidd D., Barkhof F., McConnell R., Algra P. R., Allen I. V., Revesz T. Cortical lesions in multiple sclerosis. Brain: 1999; 122 Pt 1 17 26 (Pubitemid 29046269)
346. Bobholz J. A., Rao S. M., Lobeck L., et al. fMRI study of episodic memory in relapsing-remitting MS: correlation with T2 lesion volume. Neurology: 2006; 67 9 1640 1645 (Pubitemid 44747937)
347. Chiaravalloti N., Hillary F., Ricker J., et al. Cerebral activation patterns during working memory performance in multiple sclerosis using FMRI. J Clin Exp Neuropsychol: 2005; 27 1 33 54 (Pubitemid 40392831)
348. Mainero C., Caramia F., Pozzilli C., et al. fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis. Neuroimage: 2004; 21 3 858 867 (Pubitemid 38314947)
349. Staffen W., Mair A., Zauner H., et al. Cognitive function and fMRI in patients with multiple sclerosis: evidence for compensatory cortical activation during an attention task. Brain: 2002; 125 Pt 6 1275 1282 (Pubitemid 34587137)
350. Wishart H. A., Saykin A. J., McDonald B. C., et al. Brain activation patterns associated with working memory in relapsing-remitting MS. Neurology: 2004; 62 2 234 238 (Pubitemid 38167130)
351. Genova H. M., Hillary F. G., Wylie G., Rypma B., Deluca J. Examination of processing speed deficits in multiple sclerosis using functional magnetic resonance imaging. J Int Neuropsychol Soc: 2009; 15 3 383 393
352. Nebel K., Wiese H., Seyfarth J., et al. Activity of attention related structures in multiple sclerosis patients. Brain Res: 2007; 1151 150 160 (Pubitemid 46709869)
353. Penner I. K., Rausch M., Kappos L., Opwis K., Radü E. W. Analysis of impairment related functional architecture in MS patients during performance of different attention tasks. J Neurol: 2003; Jul; 250 4 461 472 (Pubitemid 36459754)
354. Filippi M., Agosta F., Spinelli E. G., Rocca M. A. Imaging resting state brain function in multiple sclerosis. J Neurol: 2013; Jul; 260 7 1709 1713
355. Rocca M. A., Absinta M., Filippi M. The role of advanced magnetic resonance imaging techniques in primary progressive MS. J Neurol: 2012; 259 4 611 621
356. Rocca M. A., Valsasina P., Martinelli V., et al. Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. Neurology: 2012; 79 14 1449 1457
357. Faivre A., Rico A., Zaaraoui W., et al. Assessing brain connectivity at rest is clinically relevant in early multiple sclerosis. Mult Scler: 2012; 18 9 1251 1258
358. Hawellek D. J., Hipp J. F., Lewis C. M., Corbetta M., Engel A. K. Increased functional connectivity indicates the severity of cognitive impairment in multiple sclerosis. Proc Natl Acad Sci U S A: 2011; 108 47 19066 19071
359. Loitfelder M., Filippi M., Rocca M., et al. Abnormalities of resting state functional connectivity are related to sustained attention deficits in MS. PLoS ONE: 2012; 7 8 e42862
360. Bonavita S., Gallo A., Sacco R., et al. Distributed changes in default-mode resting-state connectivity in multiple sclerosis. Mult Scler: 2011; 17 4 411 422
361. Sun X., Tanaka M., Kondo S., Okamoto K., Hirai S. Clinical significance of reduced cerebral metabolism in multiple sclerosis: a combined PET and MRI study. Ann Nucl Med: 1998; 12 2 89 94 (Pubitemid 28259387)
362. Paulesu E., Perani D., Fazio F., et al. Functional basis of memory impairment in multiple sclerosis: a[18F]FDG PET study. Neuroimage: 1996; 4 2 87 96 (Pubitemid 26337401)
363. Pozzilli C., Fieschi C., Perani D., et al. Relationship between corpus callosum atrophy and cerebral metabolic asymmetries in multiple sclerosis. J Neurol Sci: 1992; 112 1-2 51 57
364. Blinkenberg M., Jensen C. V., Holm S., Paulson O. B., Sorensen P. S. A longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS. Neurology: 1999; 53 1 149 153 (Pubitemid 29329663)
365. Banati R. B., Newcombe J., Gunn R. N., et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain: 2000; May; 123 Pt 11 2321 2337
366. Debruyne J. C., Versijpt J., Van Laere K. J., et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol: 2003; May; 10 3 257 264 (Pubitemid 36609480)
367. Versijpt J., Debruyne J. C., Van Laere K. J., et al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. Mult Scler: 2005; 11 2 127 134 (Pubitemid 40403248)
368. Politis M., Giannetti P., Su P., et al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology: 2012; 79 6 523 530
369. Chang L., Ernst T., Leonido-Yee M., Walot I., Singer E. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology: 1999; 52 1 100 108 (Pubitemid 29044406)
370. Küper M., Rabe K., Esser S., et al. Structural gray and white matter changes in patients with HIV. J Neurol: 2011; 258 6 1066 1075
371. Ragin A. B., Du H., Ochs R., et al. Structural brain alterations can be detected early in HIV infection. Neurology: 2012; 79 24 2328 2334
372. Thompson P. M., Dutton R. A., Hayashi K. M., et al. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci U S A: 2005; 102 43 15647 15652 (Pubitemid 41528110)
373. Chang L., Ernst T., Tornatore C., et al. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology: 1997; 48 4 836 845
374. Mark A. S., Atlas S. W. Progressive multifocal leukoencephalopathy in patients with AIDS: appearance on MR images. Radiology: 1989; 173 2 517 520 (Pubitemid 19264617)
375. Paul R. H., Ernst T., Brickman A. M., et al. ACTG 301 team; ACTG 700 team; HIV MRS Consortium. Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV. J Int Neuropsychol Soc: 2008; 14 5 725 733
376. Ragin A. B., Storey P., Cohen B. A., Epstein L. G., Edelman R. R. Whole brain diffusion tensor imaging in HIV-associated cognitive impairment. AJNR Am J Neuroradiol: 2004; 25 2 195 200 (Pubitemid 38235295)
377. Tate D. F., Conley J., Paul R. H., et al. Quantitative diffusion tensor imaging tractography metrics are associated with cognitive performance among HIV-infected patients. Brain Imaging Behav: 2010; 4 1 68 79
378. Leite S. C., Corrêa D. G., Doring T. M., et al. Diffusion tensor MRI evaluation of the corona radiata, cingulate gyri, and corpus callosum in HIV patients. J Magn Reson Imaging: 2013
379. Garvey L. J., Pavese N., Ramlackhansingh A., et al. Acute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation. PLoS ONE: 2012; 7 7 e38980
380. Tucker K. A., Robertson K. R., Lin W., et al. Neuroimaging in human immunodeficiency virus infection. J Neuroimmunol: 2004; 157 1-2 153 162 (Pubitemid 39576650)
381. Chang L., Speck O., Miller E. N., et al. Neural correlates of attention and working memory deficits in HIV patients. Neurology: 2001; 57 6 1001 1007 (Pubitemid 32880193)
382. Ernst T., Chang L., Jovicich J., Ames N., Arnold S. Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology: 2002; 59 9 1343 1349 (Pubitemid 35285984)
383. Maki P. M., Cohen M. H., Weber K., et al. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women: a preliminary study. Neurology: 2009; 72 19 1661 1668
384. Melrose R. J., Tinaz S., Castelo J. M., Courtney M. G., Stern C. E. Compromised fronto-striatal functioning in HIV: an fMRI investigation of semantic event sequencing. Behav Brain Res: 2008; 188 2 337 347
385. Thomas J. B., Brier M. R., Snyder A. Z., Vaida F. F., Ances B. M. Pathways to neurodegeneration: effects of HIV and aging on resting-state functional connectivity. Neurology: 2013; 80 13 1186 1193
386. Chang L., Ernst T., Leonido-Yee M., Speck O. Perfusion MRI detects rCBF abnormalities in early stages of HIV-cognitive motor complex. Neurology: 2000; 54 2 389 396 (Pubitemid 30078070)
387. Maini C. L., Pigorini F., Pau F. M., et al. Cortical cerebral blood flow in HIV-1-related dementia complex. Nucl Med Commun: 1990; 11 9 639 648 (Pubitemid 20319687)
388. Tracey I., Hamberg L. M., Guimaraes A. R., et al. Increased cerebral blood volume in HIV-positive patients detected by functional MRI. Neurology: 1998; 50 6 1821 1826 (Pubitemid 28283258)
389. Rottenberg D. A., Sidtis J. J., Strother S. C., et al. Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med: 1996; Jul; 37 7 1133 1141 (Pubitemid 26329520)
390. Rottenberg D. A., Moeller J. R., Strother S. C., et al. The metabolic pathology of the AIDS dementia complex. Ann Neurol: 1987; 22 6 700 706 (Pubitemid 18018465)
391. Davison J. M., Subramaniam R. M., Surasi D. S., Cooley T., Mercier G., Peller P. J. FDG PET/CT in patients with HIV. AJR Am J Roentgenol: 2011; 197 2 284 294
392. Pascal S., Resnick L., Barker W. W., et al. Metabolic asymmetries in asymptomatic HIV-1 seropositive subjects: relationship to disease onset and MRI findings. J Nucl Med: 1991; Sept; 32 9 1725 1729
393. Wang G. J., Chang L., Volkow N. D., et al. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain: 2004; 127 Pt 11 2452 2458 (Pubitemid 39472973)
394. Ioannides P., Karacostas D. Neuroimaging in human prion disease: Searching in the mist. World J Radiol: 2009; Dec 31; 1 1 45 49
395. Macfarlane R. G., Wroe S. J., Collinge J., Yousry T. A., Jäger H. R. Neuroimaging findings in human prion disease. J Neurol Neurosurg Psychiatry: 2007; 78 7 664 670 (Pubitemid 46998832)
396. Puoti G., Bizzi A., Forloni G., Safar J. G., Tagliavini F., Gambetti P. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol: 2012; 11 7 618 628
397. Tschampa H. J., Kallenberg K., Urbach H., et al. MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. Brain: 2005; 128 Pt 9 2026 2033 (Pubitemid 41253270)
398. Schröter A., Zerr I., Henkel K., Tschampa H. J., Finkenstaedt M., Poser S. Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. Arch Neurol: 2000; 57 12 1751 1757
399. Ukisu R., Kushihashi T., Kitanosono T., et al. Serial diffusion-weighted MRI of Creutzfeldt-Jakob disease. AJR Am J Roentgenol: 2005; 184 2 560 566 (Pubitemid 46657267)
400. Shiga Y., Miyazawa K., Sato S., et al. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology: 2004; 63 3 443 449 (Pubitemid 39031372)
401. Meissner B., Körtner K., Bartl M., et al. Sporadic Creutzfeldt-Jakob disease: magnetic resonance imaging and clinical findings. Neurology: 2004; 63 3 450 456 (Pubitemid 39031373)
402. Kim J. H., Choi B. S., Jung C., Chang Y., Kim S. Diffusion-weighted imaging and magnetic resonance spectroscopy of sporadic Creutzfeldt-Jakob disease: correlation with clinical course. Neuroradiology: 2011; 53 12 939 945
403. Collie D. A., Summers D. M., Sellar R. J., et al. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. AJNR Am J Neuroradiol: 2003; 24 8 1560 1569 (Pubitemid 37151720)
404. Zeidler M., Sellar R. J., Collie D. A., et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet: 2000; 355 9213 1412 1418 (Pubitemid 30215964)
405. Will R. G., Zeidler M., Stewart G. E., et al. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol: 2000; 47 5 575 582 (Pubitemid 30261892)
406. Pandya H. G., Coley S. C., Wilkinson I. D., Griffiths P. D. Magnetic resonance spectroscopic abnormalities in sporadic and variant Creutzfeldt-Jakob disease. Clin Radiol: 2003; 58 2 148 153 (Pubitemid 36221676)
407. Galanaud D., Haik S., Linguraru M. G., et al. Combined diffusion imaging and MR spectroscopy in the diagnosis of human prion diseases. AJNR Am J Neuroradiol: 2010; 31 7 1311 1318
408. de Silva R., Patterson J., Hadley D., Russell A., Turner M., Zeidler M. Single photon emission computed tomography in the identification of new variant Creutzfeldt-Jakob disease: case reports. BMJ: 1998; 316 7131 593 594 (Pubitemid 28120991)
409. Meissner B., Kallenberg K., Sanchez-Juan P., et al. MRI and clinical syndrome in dura mater-related Creutzfeldt-Jakob disease. J Neurol: 2009; 256 3 355 363
410. García Santos J. M., López Corbalán J. A., Martínez-Lage J. F., Sicilia Guillén J. CT. CT and MRI in iatrogenic and sporadic Creutzfeldt-Jakob disease: as far as imaging perceives. Neuroradiology: 1996; 38 3 226 231
411. du Plessis D. G. Prion protein disease and neuropathology of prion disease. Neuroimaging Clin N Am: 2008; 18 1 163 182, ix ix
412. Fulbright R. K., Hoffmann C., Lee H., Pozamantir A., Chapman J., Prohovnik I. MR imaging of familial Creutzfeldt-Jakob disease: a blinded and controlled study. AJNR Am J Neuroradiol: 2008; 29 9 1638 1643
413. Wimberger D., Uranitsch K., Schindler E., Kramer J. Gerstmann- Sträussler-Scheinker syndrome: MR findings. J Comput Assist Tomogr: 1993; 17 2 326 327
414. Arata H., Takashima H., Hirano R., et al. Early clinical signs and imaging findings in Gerstmann-Sträussler-Scheinker syndrome (Pro102Leu). Neurology: 2006; 66 11 1672 1678 (Pubitemid 43964621)
415. Aralasmak A., Crain B. J., Zou W. Q., Yousem D. M. A prion disease-possible Gerstmann-Straussler-Scheinker disease: a case report. J Comput Assist Tomogr: 2006; 30 1 135 139 (Pubitemid 43052314)
416. Waldman A. D., Cordery R. J., MacManus D. G., Godbolt A., Collinge J., Rossor M. N. Regional brain metabolite abnormalities in inherited prion disease and asymptomatic gene carriers demonstrated in vivo by quantitative proton magnetic resonance spectroscopy. Neuroradiology: 2006; 48 6 428 433 (Pubitemid 43923167)
417. Konaka K., Kaido M., Okuda Y., et al. Proton magnetic resonance spectroscopy of a patient with Gerstmann-Straussler-Scheinker disease. Neuroradiology: 2000; 42 9 662 665
418. Park M. J., Jo H. Y., Cheon S. M., Choi S. S., Kim Y. S., Kim J. W. A case of gerstmann-sträussler-scheinker disease. J Clin Neurol: 2010; 6 1 46 50
419. Zerr I., Giese A., Windl O., et al. Phenotypic variability in fatal familial insomnia (D178N-129M) genotype. Neurology: 1998; 51 5 1398 1405 (Pubitemid 28520566)
420. Almer G., Hainfellner J. A., Brücke T., et al. Fatal familial insomnia: a new Austrian family. Brain: 1999; 122 Pt 1 5 16 (Pubitemid 29046268)
421. Lodi R., Parchi P., Tonon C., et al. Magnetic resonance diagnostic markers in clinically sporadic prion disease: a combined brain magnetic resonance imaging and spectroscopy study. Brain: 2009; 132 Pt 10 2669 2679
422. Matoba M., Tonami H., Miyaji H., Yokota H., Yamamoto I. Creutzfeldt-Jakob disease: serial changes on diffusion-weighted MRI. J Comput Assist Tomogr: 2001; 25 2 274 277 (Pubitemid 32222896)
423. Montagna P., Gambetti P., Cortelli P., Lugaresi E. Familial and sporadic fatal insomnia. Lancet Neurol: 2003; 2 3 167 176 (Pubitemid 37443320)
424. Jagust W. J., Bandy D., Chen K., et al. Alzheimer's Disease Neuroimaging Initiative The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement: 2010; 6 3 221 229
425. Swaminathan S., Shen L., Risacher S. L., et al. Alzheimer's Disease Neuroimaging Initiative Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging Behav: 2012; Mar; 6 1 1 15
426. Risacher S. L., Saykin A. J. Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Annu Rev Clin Psychol: 2013; 9 621 648
427. Kassubek J., Juengling F. D., Kioschies T., et al. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry: 2004; 75 2 213 220 (Pubitemid 38183526)